Progressive Myopia Clinical Trial
— DLTCAMOfficial title:
Randomized Controlled Trial of Different Lens Treatments on Chinese Adolescent Myopia
The purpose of this study is to determine the efficacy of different lens treatments (normal spectacle lens, ortho-K, & Myovision) on myopia control in Chinese adolescent patients.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 10 Years to 15 Years |
Eligibility |
Inclusion Criteria: - Adolescent myopia patients - Myopic refraction between -1.00D and -4.50D - Astigmatism equal or less than -1.50D - Normal break up time of tear film (BUT > 10s) Exclusion Criteria: - Existence of any ocular diseases except ametropia - Hyperopia - Severe dry eye |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Ophthalmology Department of Peking University People's Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of Ocular Axial Length | Ocular axial length (AL), which increases with age, will be measured 3 times by an IOLMaster. The first AL examination was considered as the baseline data, and will be repeated 6 and 12 months later. | Baseline, 6 months, 12 months | No |
Secondary | Change of Spherical Equivalent Refraction | Spherical Equivalent Refraction (SER), which usually changes from time to time, will be measured 3 times by an open field auto-refractometer. The first SER examination was considered as the baseline data, and will be repeated 6 and 12 months later. | Baseline, 6 months, 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05667454 -
MAD Trial: Myopia Atropine Dose
|
Phase 3 |